Index
RUT
Market Cap
7.49B
Enterprise Value
10.23B
Income
157.36M
Sales
3.12B
Book/sh
0.10
Cash/sh
0.39
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
8500
IPO
Dec 19, 1995
P/E
44.89
Forward P/E
17.83
PEG
0.87
P/S
2.40
P/B
207.99
P/C
54.97
P/FCF
92.36
EV/EBITDA
15.24
EV/Sales
3.28
Quick Ratio
1.44
Current Ratio
2.20
Debt/Eq
84.55
LT Debt/Eq
80.87
Option/Short
Yes / Yes
EPS (ttm)
0.48
EPS next Y
1.21
EPS next Q
0.24
EPS this Y
24.10%
EPS next Y
17.13%
EPS next 5Y
20.57%
EPS past 3/5Y
- -18.36%
Sales past 3/5Y
10.92% 8.66%
EPS Y/Y TTM
4917.17%
Sales Y/Y TTM
9.28%
EPS Q/Q
152.81%
Sales Q/Q
9.89%
Insider Own
55.02%
Insider Trans
-0.25%
Inst Own
48.03%
Inst Trans
1.32%
ROA
4.37%
ROE
-
ROIC
5.82%
Gross Margin
39.32%
Oper. Margin
15.30%
Profit Margin
5.05%
SMA20
6.62%
SMA50
12.49%
SMA200
36.64%
Trades
Shs Outstand
319.33M
Shs Float
156.65M
52W High
21.67 -0.76%
52W Low
9.99 115.32%
Volatility
2.56% 3.04%
ATR (14)
0.63
RSI (14)
67.66
Beta
1.26
Rel Volume
0.98
Avg Volume
2.82M
Volume
2,765,641
Perf Week
5.54%
Perf Month
7.17%
Perf Quarter
14.11%
Perf Half Y
67.65%
Perf YTD
70.71%
Perf Year
115.10%
Perf 3Y
454.38%
Perf 5Y
291.80%
Perf 10Y
3.91%
Prev Close
21.35
Price
21.51
Change %
0.75%
Analysts 11 incl. previous ratings
Rating Distribution 8 Buy · 3 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Sep 23, 2026 Initiated O Oppenheimer
Outperform $27 +25.5% Sep 09, 2026 Initiated L Leerink Partners
Outperform $23 +6.9% Apr 17, 2026 Initiated U UBS
Buy $19 -11.7% Dec 09, 2025 Initiated B Barclays
Overweight $15 -30.3% Jun 06, 2025 Initiated G Goldman
Buy $12 -44.2% Feb 24, 2025 Upgrade J JP Morgan
Neutral → Overweight $9 → $12 -44.2% Sep 06, 2024 Upgrade J JP Morgan
Underweight → Neutral $9 -58.2% Apr 07, 2021 Resumed R RBC Capital Mkts
Sector Perform $5 -76.8% Mar 08, 2021 Upgrade G Goldman
Sell → Buy $4 → $6.50 -69.8% Dec 14, 2020 Upgrade G Guggenheim
Neutral → Buy $5.50 -74.4% Dec 14, 2020 Upgrade B Barclays
Equal Weight → Overweight $4.50 → $6 -72.1% Jul 27, 2020 Initiated G Goldman
Sell $4 -81.4% May 12, 2020 Upgrade G Guggenheim
Sell → Neutral Dec 12, 2019 Downgrade R Raymond James
Outperform → Mkt Perform Nov 12, 2019 Downgrade J JP Morgan
Neutral → Underweight Nov 07, 2019 Downgrade S SVB Leerink
Outperform → Mkt Perform Jul 22, 2019 Upgrade S SVB Leerink
Mkt Perform → Outperform $11 → $5 -76.8% Jul 11, 2019 Downgrade R RBC Capital Mkts
Outperform → Sector Perform $11 → $6 -72.1% Jul 08, 2019 Upgrade P Piper Jaffray
Neutral → Overweight Jun 11, 2019 Initiated B Barclays
Equal Weight $9 -58.2%
Show Previous Ratings
Oct-26-26 04:06PM
Oct-08-26 08:00AM
Sep-21-26 06:17AM
(The Wall Street Journal)
+7.75%
Sep-18-26 04:01PM
Aug-10-26 08:00AM
05:02PM
Loading…
Jul-30-26 05:02PM
06:00AM
Jul-17-26 08:00AM
Jul-09-26 04:05PM
Jun-29-26 03:00AM
Jun-10-26 10:09AM
Jun-05-26 08:00AM
Jun-04-26 08:00AM
Jun-01-26 08:00AM
May-07-26 04:01PM
06:17AM
Loading…
Apr-22-26 06:17AM
06:00AM
Apr-20-26 08:00AM
Apr-14-26 08:00AM
Apr-10-26 08:11PM
08:11PM
08:11PM
Apr-09-26 08:00AM
Apr-07-26 04:01PM
08:00AM
Mar-10-26 12:02AM
Mar-09-26 08:22AM
07:11AM
Mar-05-26 04:05PM
Feb-27-26 04:04PM
03:21PM
Loading…
03:21PM
10:24AM
09:30AM
09:17AM
07:15AM
06:39AM
06:00AM
Feb-25-26 10:03PM
Feb-23-26 09:40AM
09:06AM
Feb-19-26 09:53AM
Feb-18-26 04:05AM
Feb-13-26 11:26AM
Feb-12-26 11:31PM
Feb-09-26 09:40AM
Feb-06-26 01:58PM
Feb-05-26 09:40AM
Feb-04-26 11:32PM
Feb-03-26 11:23AM
Jan-28-26 04:05PM
12:10PM
09:11AM
Jan-27-26 06:02PM
12:59PM
08:00AM
Jan-25-26 11:02PM
Jan-22-26 09:40AM
Jan-15-26 09:40AM
Jan-13-26 09:04PM
Jan-10-26 02:57PM
Jan-07-26 02:55PM
Jan-06-26 11:44AM
Dec-22-25 04:01PM
04:00PM
Dec-09-25 04:01PM
Dec-05-25 08:00AM
Dec-02-25 08:00AM
08:00AM
Dec-01-25 04:01PM
Nov-28-25 10:56AM
Nov-21-25 08:04AM
Nov-19-25 10:33PM
Nov-14-25 08:44AM
05:10AM
Nov-13-25 04:01PM
Nov-11-25 11:35PM
Nov-04-25 09:33AM
Oct-31-25 01:00PM
Oct-30-25 04:30PM
09:30AM
07:15AM
06:47AM
06:14AM
(Associated Press Finance)
06:00AM
Oct-29-25 04:05PM
09:39AM
Oct-28-25 11:17PM
05:10PM
Oct-27-25 10:00AM
08:00AM
Oct-23-25 10:00AM
Oct-21-25 10:42PM
Oct-07-25 09:40AM
Oct-06-25 08:07AM
08:00AM
Oct-03-25 09:15AM
Oct-02-25 09:40AM
08:18AM
Oct-01-25 01:44PM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BUCHI J KEVIN Director Sep 11 '26 Option Exercise 14.45 20,445 295,430 95,522 Sep 14 04:10 PM Kiely John Director Aug 13 '26 Sale 17.64 50,000 882,000 210,252 Aug 14 04:29 PM Shah Nikita Executive Vice President Aug 12 '26 Sale 17.51 146,403 2,563,517 253,390 Aug 13 04:22 PM Daly Jason B. EVP, Chief Legal Officer Aug 12 '26 Sale 17.40 210,000 3,654,000 35,171 Aug 13 04:21 PM Daly Jason B. EVP, Chief Legal Officer Aug 11 '26 Sale 17.70 6,613 117,050 245,171 Aug 13 04:21 PM JOHN KIELY Director Aug 13 '26 Proposed Sale 17.59 50,000 879,714 Aug 13 04:15 PM NIKITA SHAH Officer Aug 12 '26 Proposed Sale 17.47 146,403 2,556,975 Aug 12 04:18 PM JASON DALY OFFICER Aug 11 '26 Proposed Sale 17.36 210,000 3,646,285 Aug 12 04:11 PM BUCHI J KEVIN Director Aug 11 '26 Proposed Sale 17.31 168,573 2,917,998 Aug 11 12:32 PM Autor Deborah M. Director May 11 '26 Sale 12.94 34,819 450,558 93,660 May 12 04:10 PM DEBORAH AUTOR DIRECTOR May 11 '26 Proposed Sale 12.94 34,819 450,416 May 11 06:56 PM Nark Ted C Director Nov 17 '25 Sale 11.72 50,000 586,000 291,029 Nov 19 04:21 PM Nark Ted C Director Nov 17 '25 Proposed Sale 11.82 50,000 591,250 Nov 17 03:06 PM Shah Nikita Executive Vice President Nov 12 '25 Option Exercise 2.75 131,856 362,604 278,259 Nov 14 05:13 PM Shah Nikita Executive Vice President Nov 12 '25 Sale 11.92 131,856 1,571,724 146,403 Nov 14 05:13 PM NIKITA SHAH OFFICER Nov 12 '25 Proposed Sale 11.92 131,856 1,571,723 Nov 12 05:12 PM
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.
Co-Founder Mr. Chirag K. Patel
Co-Founder Mr. Chintu Patel R.Ph.
Executive VP & CFO Mr. Anastasios G. Konidaris
Executive VP Mr. Jason B. Daly Esq.
Executive VP & Chief Human Resources Officer Ms. Nikita Shah